Tokyo, Japan

Kazuhisa Tsuruta

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2014-2017

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Kazuhisa Tsuruta: Innovator in Medicinal Treatments

Introduction

Kazuhisa Tsuruta is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medicine, particularly in the treatment of severe sepsis. With a total of four patents to his name, Tsuruta's work is recognized for its innovative approach to therapeutic treatments.

Latest Patents

Among his latest patents is a medicament designed for the therapeutic treatment and improvement of sepsis. This medicament is specifically aimed at patients suffering from severe sepsis accompanied by one or more organ dysfunctions. It utilizes thrombomodulin as an active ingredient, particularly for patients whose International Normalized Ratio (INR) value exceeds 1.4. This innovative approach highlights Tsuruta's commitment to advancing medical treatments.

Career Highlights

Kazuhisa Tsuruta is currently associated with Asahi Kasei Pharma Corporation, where he continues to develop groundbreaking medicinal solutions. His work has garnered attention for its potential to improve patient outcomes in critical care settings.

Collaborations

Tsuruta has collaborated with notable colleagues in his field, including Yoshikazu Aoki and Yutaka Osawa. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Kazuhisa Tsuruta stands out as an influential inventor in the medical field, particularly in the treatment of severe sepsis. His innovative patents and collaborations reflect his dedication to improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…